BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-280@pharmaconomics
DTSTAMP:20260707T033821Z
DTSTART;VALUE=DATE:20260405
DTEND;VALUE=DATE:20260406
SUMMARY:DNLI PDUFA — tividenofusp alfa
DESCRIPTION:The FDA's approval decision on tividenofusp alfa for Hunter syndrome is due Apr 5\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm\n\nTrack it: https://pharmaconomics.com/e/280
URL:https://pharmaconomics.com/e/280
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR